News

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of…
Read More...

Mallinckrodt plc  confirmed the enrollment of first patient for the company's Phase 1 study evaluating the safety and tolerance of ExpressGraft C9T1 skin tissue in the treatment of…
Read More...

Division of Valeant Pharmaceuticals International, Inc., Ortho Dermatologics asserted that the U.S Food and Drug Administration accepted the New Drug Application for JEMDEL  …
Read More...

PharmaMar forays into an exclusive licensing agreement with Seattle Genetics ensuring access to certain PharmaMar proprietary molecules for the development and commercialization of…
Read More...

Amgen asserted that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration will assess the data supporting the BLINCYTO supplemental Biologics License…
Read More...

Ace RNA medicines company, Arcturus Therapeutics asserted the appointment of Dr. Christine Esau, Senior Director of Translational Research, as Vice President of Research and…
Read More...

Charles River Laboratories International declared that it has ventured into a definitive agreement to obtain MPI Research for $800 million in cash. James C. Foster, Chairman and…
Read More...

Leading provider of nonclinical contract research services and research models, Envigo asserted the appointment of Lynn Lewis to the position of  Senior Vice President, Global Sales.…
Read More...

U.S Food and Drug Administration paved way for the marketing of the Viz.AI Contact application which is a type of clinical decision support software designed to interpret computed…
Read More...

Leading clinical trial technology and specialty services provider, Bracket declared the appointment of Michael Nolte as the company's Chief Executive Officer. Michael Nolte served as…
Read More...

Precision medicine biotechnology company, developing targeted oncology therapeutics, Trovagene asserted the addition of two leading  institutions,Yale Cancer Center and principal…
Read More...

Martha A.Q .Curley, PhD, RN, FAAN, a professor in Nursing Science at the University of Pennsylvania's School of Nursing, has been appointed the Ruth M. Colket Endowed Chair in Pediatric…
Read More...

Astro's Interpretation of the Phase II CONDOR trial suggests that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic…
Read More...

Astro indicates positive results of  phase II OPTIMA Clinical Trial signifying that patients with head and neck cancers associated with the human papillomavirus (HPV), including those…
Read More...

Cytobank and the U.S Food and Drug Administration collaborate to develop machine learning-based methods for characterizing the morphology of multipotent mesenchymal stromal cells…
Read More...

Quidel Corporation who is known for providing diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, sought 510 (k) Clearance from the United…
Read More...

Degenerative disc disease has long been considered an inseparable part of aging but new breakthrough research from SpinalCyte suggests a new cell-based therapy could provide a cure for…
Read More...

Biopharmaceutical company MOLOGEN AG declared having signed a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its…
Read More...

In a bid to treat metastatic radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), Exelixis declared results from a Phase 2 Investigator-sponsored trial of cabozantinib.…
Read More...

Merck declared that it will rescind protocol 019 also termed as the APECS study assessing verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid…
Read More...